Day: August 3, 2020

EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 Moderate-to-severe psoriasis affects more than 350,000 children worldwide2, with the physical and psychological burden disrupting important formative years3 Cosentyx is a proven brand, supported by long-term five-year sustained efficacy and safety data across psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), over 100 studies and with more than 340,000 patients treated worldwide since launch4,5,6,7 Approval reinforces Cosentyx leadership in immuno-dermatology and rheumatology, following recent EU approval in non-radiographic axial spondyloarthritis (nr-axSpA), with plans to expand to 10 indications over the next 10 yearsBasel, August...

Amsterdam, 3 August 2020 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces: KEY HIGHLIGHTSThe net result of Heineken Holding N.V.’s participating interest in Heineken N.V. for the first half year of 2020 amounts to €-149 millionNet revenue (beia) organic growth -16.4%; net revenue (beia) per hectolitre -3.6%Consolidated beer volume -11.5%Heineken® volume -2.5%Operating profit (beia) organic growth -52.5%Net profit (beia) €227 million, -75.8% organically FINANCIAL SUMMARY11 Consolidated figures are used throughout this report, unless otherwise stated; please refer to the Glossary for an explanation of non-GAAP measures and other terms used throughout this report.2 Organic growth shown, except for Diluted EPS (beia) which is total growth. 3 Includes acquisitions and excludes disposals on a 12 month pro-forma basis.Heineken...

MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2020 financial and operating results on the evening of Thursday, August 6, 2020.Following the press release, Celyad Oncology management will host a conference call on Friday, August 7 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2020 results and provide an update on the Company’s recent progress and upcoming milestones.Celyad Oncology First Half 2020 Conference Call DetailsDate: Friday, August 7, 2020Time: 2 p.m. CEST / 8 a.m. EDTConference ID: 13706543Dial-in: +1 201 493 6784 (International), +1 877 407 9208 (United...

L’étude mondiale de phase 2/3 recrutera jusqu’à 270 patients atteints d’une forme grave de la maladie COVID-19 sur 40 sites cliniques. L’étude a été approuvée au Royaume-Uni et en Russie et est en cours d’examen en Italie, au Brésil et au Mexique—Le recrutement dans une étude parallèle de phase 2 aux États-Unis chez des patients atteints d’une forme grave de la maladie COVID-19 devrait se terminer en août 2020– –Le dépôt potentiel de demandes d’utilisation d’urgence est prévu pour le 4e trimestre 2020TEL-AVIV, Israël et RALEIGH, Caroline du Nord, 03 août 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq : RDHL) (« RedHill » ou la « Société »), société biopharmaceutique spécialisée, a annoncé aujourd’hui avoir lancé une étude clinique mondiale de phase 2/3 évaluant...

In die globale Phase-II/III-Studie werden bis zu 270 schwer an COVID-19 erkrankte Patienten an 40 Prüfzentren aufgenommen. Die Studie wurde in Großbritannien und Russland bereits genehmigt und wird aktuell in Italien, Brasilien und Mexiko geprüft—Probandenaufnahme für eine parallel laufende Phase-II-Studie mit schwer an COVID-19 erkrankten Patienten in den USA wird voraussichtlich im August 2020 abgeschlossen—Mögliche Einreichung von Anträgen für den Einsatz in Härtefällen bereits für das vierte Quartal 2020 geplantTEL-AVIV, Israel und RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen, hat heute bekannt gegeben, dass es eine globale Phase-II/III-Studie zur Bewertung von Opaganib (Yeliva®, ABC294640)1 für...

Oslo, 3 August 2020 – Primary insider in Schibsted ASA and Adevinta ASA, Blommenholm Industrier AS, will transfer 607,851 B-shares in Schibsted ASA and 4,320,781 shares in Adevinta ASA to Beltenut AS. After these transfers, Blommenholm Industrier AS will own 30,013,354 B-shares in Schibsted ASA and 38,992,516 shares in Adevinta ASA. Blommenholm Industrier AS also owns 28,541,262 A-shares in Schibsted ASA. Following the transfers, Blommenholm Industrier AS will hold 25.04% of shares outstanding and 26.87% of voting rights in Schibsted ASA and 5.69% of shares outstanding and voting rights in Adevinta ASA.The transfers are part of an agreement between the Tinius Trust and Blommenholm Industrier AS and Beltenut AS/Jan Nagell-Erichsen to redeem the 50,000 non-voting B-shares in Blommenholm Industrier AS held by Beltenut AS. The agreement was...

Primary insider in Schibsted ASA and Adevinta ASA, Blommenholm Industrier AS, will transfer 607,851 B-shares in Schibsted ASA and 4,320,781 shares in Adevinta ASA to Beltenut AS. After these transfers, Blommenholm Industrier AS will own 30,013,354 B-shares in Schibsted ASA and 38,992,516 shares in Adevinta ASA. Blommenholm Industrier AS also owns 28,541,262 A-shares in Schibsted ASA. Following the transfers, Blommenholm Industrier AS will hold 25.04% of shares outstanding and 26.87% of voting rights in Schibsted ASA and 5.69% of shares outstanding and voting rights in Adevinta ASA.The transfers are part of an agreement between the Tinius Trust and Blommenholm Industrier AS and Beltenut AS/Jan Nagell-Erichsen to redeem the 50,000 non-voting B-shares in Blommenholm Industrier AS held by Beltenut AS. The agreement was resolved by the General...

Amsterdam, 3 August 2020 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announces:KEY HIGHLIGHTSNet revenue (beia) organic growth -16.4%; net revenue (beia) per hectolitre -3.6%Consolidated beer volume -11.5%Heineken® volume -2.5%Operating profit (beia) organic growth -52.5%Net profit (beia) €227 million, -75.8% organicallyDiluted EPS (beia) €0.39 (2019: €1.84).CEO STATEMENTDolf van den Brink, CEO and Chairman of the Executive Board, commented:“The first half of 2020 was defined by unprecedented challenges and I am very proud of our employees all around the world who are adapting quickly to new emerging realities while taking care of each other, our customers and our communities.The Heineken® brand once again demonstrated its strength with double digit growth in 14 markets and continued momentum of Heineken® 0.0.Our bottom-line was disproportionately...